Evidence map›Paper›PMID 21933020›Full record

ArticleTissue engineering. Part C, Methods2012

Compartmental hollow fiber capillary membrane-based bioreactor technology for in vitro studies on red blood cell lineage direction of hematopoietic stem cells.

Greggory J Housler, Toshio Miki, Eva Schmelzer, Christopher Pekor, Xiaokui Zhang, Lin Kang, Vanessa Voskinarian-Berse, Stewart Abbot, Katrin Zeilinger, Jörg C Gerlach

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part C, Methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Greggory J HouslerDepartment of Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15203, USA.
Toshio Miki
Eva Schmelzer
Christopher Pekor
Xiaokui Zhang
Lin Kang
Vanessa Voskinarian-Berse
Stewart Abbot
Katrin Zeilinger
Jörg C Gerlach
Bristol-Myers Squibb (Switzerland) · CHUniversity of Pittsburgh · USMcGowan Institute for Regenerative Medicine · USBerlin-Brandenburger Centrum für Regenerative Therapien · DE

Funding

3D Culture of mES Cells in Four-Compartment BioreactorsR21EB005739 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GERLACH, JOERG C. · 2005 to 2006
$385k
NIBIB NIH HHS R21 EB005739-01
6 · The paper itself

Abstract

Continuous production of red blood cells (RBCs) in an automated closed culture system using hematopoietic stem cell (HSC) progenitor cell populations is of interest for clinical application because of the high demand for blood transfusions. Previously, we introduced a four-compartment bioreactor that consisted of two bundles of hollow fiber microfiltration membranes for transport of culture medium (forming two medium compartments), interwoven with one bundle of hollow fiber membranes for transport of oxygen (O(2)), carbon dioxide (CO(2)), and other gases (forming one gas compartment). Small-scale prototypes were developed of the three-dimensional (3D) perfusion cell culture systems, which enable convection-based mass transfer and integral oxygenation in the cell compartment. CD34(+) HSC were isolated from human cord blood units using a magnetic separation procedure. Cells were inoculated into 2- or 8-mL scaled-down versions of the previously designed 800-mL cell compartment devices and perfused with erythrocyte proliferation and differentiation medium. First, using the small-scale 2-mL analytical scale bioreactor, with an initial seeding density of 800,000 cells/mL, we demonstrated approximately 100-fold cell expansion and differentiation after 7 days of culture. An 8-mL laboratory-scale bioreactor was then used to show pseudocontinuous production by intermediately harvesting cells. Subsequently, we were able to use a model to demonstrate semicontinuous production with up to 14,288-fold expansion using seeding densities of 800,000 cells/mL. The down-scaled culture technology allows for expansion of CD34(+) cells and stimulating these progenitors towards RBC lineage, expressing approximately 40% CD235(+) and enucleation. The 3D perfusion technology provides an innovative tool for studies on RBC production, which is scalable.

Indexed as

BioreactorsCell LineageMembranes, ArtificialAcrylic ResinsAntigens, SurfaceCell CountCell Culture TechniquesCell DifferentiationCells, CulturedCell SurvivalErythrocytesFlow CytometryFluorescent Antibody TechniqueGlucoseHematopoietic Stem CellsHumansAcrylic ResinsAntigens, SurfaceGlucoseLactic AcidMembranes, Artificial

Identifiers

PMID21933020
PMCPMC3262978
OpenAlexW2170125660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.